The global market for HIV Vaccine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
AIDS, or Acquired Immunodeficiency Syndrome (AIDS), is caused by the human immunodeficiency virus (HIV), also known as the AIDS virus. HIV can specifically attack and destroy human immune cells, causing damage to the human immune system, gradual loss of related immune functions, and gradually becoming the target of many diseases, leading to various serious opportunistic infections, tumors, etc. At present, AIDS has become an important public health issue that seriously threatens the health of people around the world. In 1981, doctors discovered the first known case of HIV in the United States, and since then, more than 40 million people have died from the virus. According to data from the United Nations AIDS Program, men who have sex with men, female sex workers and their clients, transgender people, and people who inject drugs are at high risk. The virus is transmitted through the exchange of body fluids of infected people, such as blood, semen, and vaginal excrement. The most common is during unprotected sex, pregnancy and childbirth, transfusion of contaminated blood, or sharing of hypodermic needles. The human body cannot completely eliminate HIV. Therefore, once infected with the virus, an individual will remain HIV positive for life. However, through antiretroviral therapy (ART) drug treatment, HIV can be controlled, its progression can be significantly slowed, and gradually become a "chronic disease". In theory, before the emergence of curative drugs, AIDS patients need to take medication for life. Although there are relatively many existing antiviral therapies, they all have a clear disadvantage: long taking cycles and short intervals. Once the medication is stopped or missed, it will lead to the deterioration of AIDS; and long-term medication may also cause problems such as drug resistance and liver damage. Historically, vaccines have been the most effective means of preventing or even eradicating infectious diseases. They can safely and cost-effectively prevent disease, disability and death. HIV vaccine is a potential vaccine that can be both a preventive vaccine and a therapeutic vaccine, meaning that it can protect individuals from HIV infection and treat HIV-infected people. In theory, it can have a significant impact on transmission rates and help control epidemics.
North American market for HIV Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for HIV Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of HIV Vaccine include Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, HKUMed, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for HIV Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HIV Vaccine.
The HIV Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Million Person) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global HIV Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HIV Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Johnson and Johnson (Janssen)
Sanofi-Pasteur
Uvax Bio
AELIX Therapeutics
IAVI
HKUMed
Segment by Type
Viral Vector Vaccines
Recombinant Protein Vaccines
Nucleic Acid Vaccines (including mRNA Vaccines)
Other Vaccines
Segment by Application
Preventive Vaccine
Therapeutic Vaccine
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of HIV Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of HIV Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 HIV Vaccine Market Overview
1.1 Product Definition
1.2 HIV Vaccine by Type
1.2.1 Global HIV Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Viral Vector Vaccines
1.2.3 Recombinant Protein Vaccines
1.2.4 Nucleic Acid Vaccines (including mRNA Vaccines)
1.2.5 Other Vaccines
1.3 HIV Vaccine by Application
1.3.1 Global HIV Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Preventive Vaccine
1.3.3 Therapeutic Vaccine
1.4 Global HIV Vaccine Market Size Estimates and Forecasts
1.4.1 Global HIV Vaccine Revenue 2020-2031
1.4.2 Global HIV Vaccine Sales 2020-2031
1.4.3 Global HIV Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 HIV Vaccine Market Competition by Manufacturers
2.1 Global HIV Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global HIV Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global HIV Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of HIV Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of HIV Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of HIV Vaccine, Product Type & Application
2.7 Global Key Manufacturers of HIV Vaccine, Date of Enter into This Industry
2.8 Global HIV Vaccine Market Competitive Situation and Trends
2.8.1 Global HIV Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest HIV Vaccine Players Market Share by Revenue
2.8.3 Global HIV Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global HIV Vaccine Market Scenario by Region
3.1 Global HIV Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global HIV Vaccine Sales by Region: 2020-2031
3.2.1 Global HIV Vaccine Sales by Region: 2020-2025
3.2.2 Global HIV Vaccine Sales by Region: 2026-2031
3.3 Global HIV Vaccine Revenue by Region: 2020-2031
3.3.1 Global HIV Vaccine Revenue by Region: 2020-2025
3.3.2 Global HIV Vaccine Revenue by Region: 2026-2031
3.4 North America HIV Vaccine Market Facts & Figures by Country
3.4.1 North America HIV Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America HIV Vaccine Sales by Country (2020-2031)
3.4.3 North America HIV Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe HIV Vaccine Market Facts & Figures by Country
3.5.1 Europe HIV Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe HIV Vaccine Sales by Country (2020-2031)
3.5.3 Europe HIV Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific HIV Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific HIV Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific HIV Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific HIV Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America HIV Vaccine Market Facts & Figures by Country
3.7.1 Latin America HIV Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America HIV Vaccine Sales by Country (2020-2031)
3.7.3 Latin America HIV Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa HIV Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa HIV Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa HIV Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa HIV Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global HIV Vaccine Sales by Type (2020-2031)
4.1.1 Global HIV Vaccine Sales by Type (2020-2025)
4.1.2 Global HIV Vaccine Sales by Type (2026-2031)
4.1.3 Global HIV Vaccine Sales Market Share by Type (2020-2031)
4.2 Global HIV Vaccine Revenue by Type (2020-2031)
4.2.1 Global HIV Vaccine Revenue by Type (2020-2025)
4.2.2 Global HIV Vaccine Revenue by Type (2026-2031)
4.2.3 Global HIV Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global HIV Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global HIV Vaccine Sales by Application (2020-2031)
5.1.1 Global HIV Vaccine Sales by Application (2020-2025)
5.1.2 Global HIV Vaccine Sales by Application (2026-2031)
5.1.3 Global HIV Vaccine Sales Market Share by Application (2020-2031)
5.2 Global HIV Vaccine Revenue by Application (2020-2031)
5.2.1 Global HIV Vaccine Revenue by Application (2020-2025)
5.2.2 Global HIV Vaccine Revenue by Application (2026-2031)
5.2.3 Global HIV Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global HIV Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Johnson and Johnson (Janssen)
6.1.1 Johnson and Johnson (Janssen) Company Information
6.1.2 Johnson and Johnson (Janssen) Description and Business Overview
6.1.3 Johnson and Johnson (Janssen) HIV Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Johnson and Johnson (Janssen) HIV Vaccine Product Portfolio
6.1.5 Johnson and Johnson (Janssen) Recent Developments/Updates
6.2 Sanofi-Pasteur
6.2.1 Sanofi-Pasteur Company Information
6.2.2 Sanofi-Pasteur Description and Business Overview
6.2.3 Sanofi-Pasteur HIV Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi-Pasteur HIV Vaccine Product Portfolio
6.2.5 Sanofi-Pasteur Recent Developments/Updates
6.3 Uvax Bio
6.3.1 Uvax Bio Company Information
6.3.2 Uvax Bio Description and Business Overview
6.3.3 Uvax Bio HIV Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Uvax Bio HIV Vaccine Product Portfolio
6.3.5 Uvax Bio Recent Developments/Updates
6.4 AELIX Therapeutics
6.4.1 AELIX Therapeutics Company Information
6.4.2 AELIX Therapeutics Description and Business Overview
6.4.3 AELIX Therapeutics HIV Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 AELIX Therapeutics HIV Vaccine Product Portfolio
6.4.5 AELIX Therapeutics Recent Developments/Updates
6.5 IAVI
6.5.1 IAVI Company Information
6.5.2 IAVI Description and Business Overview
6.5.3 IAVI HIV Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 IAVI HIV Vaccine Product Portfolio
6.5.5 IAVI Recent Developments/Updates
6.6 HKUMed
6.6.1 HKUMed Company Information
6.6.2 HKUMed Description and Business Overview
6.6.3 HKUMed HIV Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 HKUMed HIV Vaccine Product Portfolio
6.6.5 HKUMed Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 HIV Vaccine Industry Chain Analysis
7.2 HIV Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 HIV Vaccine Production Mode & Process Analysis
7.4 HIV Vaccine Sales and Marketing
7.4.1 HIV Vaccine Sales Channels
7.4.2 HIV Vaccine Distributors
7.5 HIV Vaccine Customer Analysis
8 HIV Vaccine Market Dynamics
8.1 HIV Vaccine Industry Trends
8.2 HIV Vaccine Market Drivers
8.3 HIV Vaccine Market Challenges
8.4 HIV Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Johnson and Johnson (Janssen)
Sanofi-Pasteur
Uvax Bio
AELIX Therapeutics
IAVI
HKUMed
听
听
*If Applicable.